Cargando…
Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
Purpose. To determine the immune response after dendritic cell (DC) vaccine and cytokine-induced killer cells (CIK) therapy and assess its associated toxicity, survival benefit, and changes in the quality of life (QOL) of advanced colorectal cancer (CRC) patients. Methods. We recruited 100 patients...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124766/ https://www.ncbi.nlm.nih.gov/pubmed/25136601 http://dx.doi.org/10.1155/2014/603871 |
_version_ | 1782329669995986944 |
---|---|
author | Zhu, Hui Yang, Xuejing Li, Jiali Ren, Yanjie Zhang, Tianyu Zhang, Chunze Zhang, Jintai Li, Jing Pang, Yan |
author_facet | Zhu, Hui Yang, Xuejing Li, Jiali Ren, Yanjie Zhang, Tianyu Zhang, Chunze Zhang, Jintai Li, Jing Pang, Yan |
author_sort | Zhu, Hui |
collection | PubMed |
description | Purpose. To determine the immune response after dendritic cell (DC) vaccine and cytokine-induced killer cells (CIK) therapy and assess its associated toxicity, survival benefit, and changes in the quality of life (QOL) of advanced colorectal cancer (CRC) patients. Methods. We recruited 100 patients with unresectable CRC orrelapsed CRC after surgery who received DC vaccine and CIK cells (group immunotherapy, group I), and, as a control, 251 patients who had similar characteristics and underwent similar treatments, except for this immunotherapy (group nonimmunotherapy, group NI). After a follow-up period of 489.2 ± 160.4 days, overall survival (OS) of the two groups was compared using the Kaplan-Meier method. Results. In group I, 62% of patients developed a positive delayed type hypersensitivity response, and most patients showed an improvement in physical strength (75.2%), appetite (74.2%), sleeping (72.1%), and body weight (70.1%). Adverse events were fever (29.5%), insomnia (19.2%), anorexia (9.1%), sore joints (5.4%), and skin rash (1.0%). No toxicity was observed in patients treated with DC vaccine and CIK therapy. OS was significantly longer in group I than in group NI (P = 0.043). Conclusion. DC vaccine and CIK therapy were safe and could induce an immune response against CRC, thereby improving QOL and prolonging OS. |
format | Online Article Text |
id | pubmed-4124766 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-41247662014-08-18 Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy Zhu, Hui Yang, Xuejing Li, Jiali Ren, Yanjie Zhang, Tianyu Zhang, Chunze Zhang, Jintai Li, Jing Pang, Yan Biomed Res Int Clinical Study Purpose. To determine the immune response after dendritic cell (DC) vaccine and cytokine-induced killer cells (CIK) therapy and assess its associated toxicity, survival benefit, and changes in the quality of life (QOL) of advanced colorectal cancer (CRC) patients. Methods. We recruited 100 patients with unresectable CRC orrelapsed CRC after surgery who received DC vaccine and CIK cells (group immunotherapy, group I), and, as a control, 251 patients who had similar characteristics and underwent similar treatments, except for this immunotherapy (group nonimmunotherapy, group NI). After a follow-up period of 489.2 ± 160.4 days, overall survival (OS) of the two groups was compared using the Kaplan-Meier method. Results. In group I, 62% of patients developed a positive delayed type hypersensitivity response, and most patients showed an improvement in physical strength (75.2%), appetite (74.2%), sleeping (72.1%), and body weight (70.1%). Adverse events were fever (29.5%), insomnia (19.2%), anorexia (9.1%), sore joints (5.4%), and skin rash (1.0%). No toxicity was observed in patients treated with DC vaccine and CIK therapy. OS was significantly longer in group I than in group NI (P = 0.043). Conclusion. DC vaccine and CIK therapy were safe and could induce an immune response against CRC, thereby improving QOL and prolonging OS. Hindawi Publishing Corporation 2014 2014-07-17 /pmc/articles/PMC4124766/ /pubmed/25136601 http://dx.doi.org/10.1155/2014/603871 Text en Copyright © 2014 Hui Zhu et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Zhu, Hui Yang, Xuejing Li, Jiali Ren, Yanjie Zhang, Tianyu Zhang, Chunze Zhang, Jintai Li, Jing Pang, Yan Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy |
title | Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy |
title_full | Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy |
title_fullStr | Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy |
title_full_unstemmed | Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy |
title_short | Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy |
title_sort | immune response, safety, and survival and quality of life outcomes for advanced colorectal cancer patients treated with dendritic cell vaccine and cytokine-induced killer cell therapy |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124766/ https://www.ncbi.nlm.nih.gov/pubmed/25136601 http://dx.doi.org/10.1155/2014/603871 |
work_keys_str_mv | AT zhuhui immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy AT yangxuejing immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy AT lijiali immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy AT renyanjie immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy AT zhangtianyu immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy AT zhangchunze immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy AT zhangjintai immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy AT lijing immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy AT pangyan immuneresponsesafetyandsurvivalandqualityoflifeoutcomesforadvancedcolorectalcancerpatientstreatedwithdendriticcellvaccineandcytokineinducedkillercelltherapy |